Şerife Yılmaz Gürbüz

Dr. Şerife Yılmaz Gürbüz

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
YTYeşim Tuyji Tok
Yeşim Tuyji Tok
RSRabia Can Sarinoglu
Rabia Can Sarinoglu
SOSeyhan Ordekci
Seyhan Ordekci
ŞGŞerife Yılmaz Gürbüz
Şerife Yılmaz Gürbüz
GOGunes Ozcolpan
Gunes Ozcolpan
GCGulden Celik
Gulden Celik
Numerous vaccines have been generated to decrease the morbidity and mortality of COVID-19. This study aims to evaluate the immunogenicity of the heterologous boosts by BioNTech against homologous boosts by CoronaVac at three-month intervals in two health care worker (HCW) cohorts, with or without prior COVID-19, for one year post-vaccination. This is a prospective cohort study in which the humoral responses of 386 HCWs were followed-up longitudinally in six main groups according to their previous COVID-19 exposure and vaccination status. Anti-SARS-CoV-2 spike-RBD total antibody levels were measured and SARS-CoV-2 neutralization antibody (NAbs) responses against the ancestral Wuhan and the Omicron variant were evaluated comparatively using international standard serum for Wuhan and Omicron, as well as with the aid of a conversion tool. The anti-SARS-CoV-2 spike-RBD total Ab and Nab difference between with and without prior COVID-19, three months after two-dose primary vaccination with CoronaVac, was statistically significant (p = 0.001). In the subsequent follow-ups, this difference was not observed between the groups. Those previously infected (PI) and non-previously infected (NPI) groups receiving BioNTech as the third dose had higher anti-SARS-CoV-2 spike total Ab levels (14.2-fold and 17.4-fold, respectively, p = 0.001) and Nab responses (against Wuhan and Omicron) than those receiving CoronaVac. Ab responses after booster vaccination decreased significantly in all groups at the ninth-month follow-up (p < 0.05); however, Abs were still higher in all booster received groups than that in the primary vaccination. Abs were above the protective level at the twelfth-month measurement in the entire of the second BioNTech received group as the fourth dose of vaccination. In the one-year follow-up period, the increased incidence of COVID-19 in the groups vaccinated with two or three doses of CoronaVac compared with the groups vaccinated with BioNTech as a booster suggested that continuing the heterologous CoronaVac/BioNTech vaccination, revised according to current SARS-CoV-2 variants and with at least a six-month interval booster would be an effective and safe strategy for protection against COVID-19, particularly in health care workers.


27 December 2019 in Journal of Surgery and Medicine
Verified
Journal Article
Open access
PDF file
NANergis Asgin
Nergis Asgin
ŞGŞerife Yılmaz Gürbüz
Şerife Yılmaz Gürbüz
Aim: Urinary tract infection (UTI) is a major cause of mortality and morbidity in elderly patients. In this cross-sectional study, we aimed to determine the frequency and antibiotic resistance profile of the bacteria causing UTI and contribute to the empirical treatment options in elderly patients. Methods: This study included urine culture results from 347 elderly outpatients who were referred to Karabuk Training and Research Hospital between January 2018 and June 2019. The identification and antibiotic susceptibilities of microorganisms were determined using the BD-Phoenix 100 fully automated system, and the extended-spectrum beta-lactamase (ESBL) positivity was analyzed using the combined disk diffusion method. The results were retrospectively analyzed. Results: The most common pathogens were Escherichia coli (58%), Enterococcus spp. (18%) and Klebsiella pneumoniae (11%). The rate of resistance to ampicillin, amoxicillin-clavulanic acid, trimethoprim-sulfamethoxazole (TMP-SMX), cefixime, and ciprofloxacin, which are oral antibiotics used in the treatment of UTI, was between 30% and 70%. The rate of resistance to nitrofurantoin was 3%. The gentamicin and piperacillin-tazobactam resistance were 12% and 9%, respectively. The ESBL positivity for E. coli and K. pneumoniae were 29% and 49%, respectively (P=0.03). Conclusion: The rates of resistance to oral antibiotics such as ampicillin, amoxicillin-clavulanic acid, TMP-SMX, cefixime, and ciprofloxacin, which are used treatment of UTI, were more than 20%. Therefore, these antibiotics should not be used in the empirical treatment of UTI. Instead, nitrofurantoin may be preferred in the empirical treatment of uncomplicated UTI, or gentamicin and piperacillin-tazobactam, which are parenteral antibiotics that may be used depending on the patient’s clinical condition.

30 December 2023 in Journal of Medical Topics and Updates
Verified
Journal Article
Closed access
FBFerhat Bozduman
Ferhat Bozduman
YSYusuf Secgin
Yusuf Secgin
ŞGŞerife Yılmaz Gürbüz
Şerife Yılmaz Gürbüz
ZOZulal Oner
Zulal Oner
HSHasan Solmaz
Hasan Solmaz
Background: Atmospheric pressure cold plasma is a type of non-thermal plasma used for antimicrobial activity in the health, food and agriculture sectors. This study was carried out to investigate the efficacy of atmospheric pressure cold plasma on different bacterial isolates. Materials and Methods: The study was conducted on standard reference bacterial strains; Escherichia coli (O157:H7), Bacillus subtilis (ATCC 6633), Enterobacter aerogenes (ATCC 13048), Rhodococcus equi (ATCC 6939), Salmonella typhimurium (ATCC 14028), Enterococcus feacalis (ATCC 2912) and field isolates; 12 Escherichia coli isolates, 22 Staphylococcus spp, 18 Klebsiella spp., 2 Enterococcus spp., 3 Acinetobacter spp., 8 Candida spp., 1 Morgarella mongarii, 2 Corynebacterium spp., 1 Streptococcus pyogenes. Atmospheric pressure cold plasma jet and plasma activated medium (PAM) were applied to the isolates and their efficacy was investigated. Results: As a result of the study, it was found that cold plasma was effective against Escherichia coli (O157:H7), Enterobacter aerogenes (ATCC 13048), Salmonella typhimurium, Rhodococcus equi (ATCC 6939) and Enterococcus feacalis (ATCC 2912) among standard bacterial strains, while it was effective against Streptococcus pyogenes (group A Bet) and Staphylococcus epidermidis among field isolates. Conclusions: As a result of our study, the antimicrobial activity of atmospheric pressure cold plasma and PAM was demonstrated, and we believe that it will contribute to the health, food and agriculture sectors.

30 September 2024 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
DHDemet Hacıseyitoğlu
Demet Hacıseyitoğlu
ŞGŞerife Yılmaz Gürbüz
Şerife Yılmaz Gürbüz
FEFatma Erdoğan
Fatma Erdoğan
FCFüsun Cömert
Füsun Cömert
Introduction: We investigated the effect of two preanalytical variables, temperature change and freezing-thawing of serum samples, on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG levels. Methodology: Serum samples were collected from patients who had coronavirus disease 2019 (COVID-19) prior to vaccination. Six serum samples were included, two each with high positivity (HP), low positivity (LP), and a level of close-to-detection limit (CDL) for SARS-CoV-2 IgG. Each of these six samples was divided into three tubes and placed in refrigerators at 4-8 °C, -20 °C, and -70 °C; removed from the storage temperature once per day for 20 consecutive days; and assayed for SARS-CoV-2 IgG level. Results: The coefficient of variation of all the remaining serum samples were within 95% except for CDL-1 serum at -70 °C, HP-2 serum at 4-8 °C, HP-2 serum at -20 °C, and HP-2 serum at -70 °C. The levels increased significantly when the temperature in the samples with CDL was reduced. The values in samples with LP at -20 °C and -70 °C were significantly higher than those at 4-8°C. In the case of samples with HP, the values of samples at -20 °C were higher than those in samples at 4-8 °C. There was no positive–negative change during any of the freeze-thaw cycles. Conclusions: Antibody value in the samples at 4-8 °C remained stable throughout the 20 freeze-thaw cycles. The antibody value of the samples at -20 °C and -70 °C tended to elevate.

30 April 2025 in ANKEM DERGİSİ
Verified
Journal Article
Open access
PDF file
BDBüşra Dönmez
Büşra Dönmez
ŞGŞerife Yılmaz Gürbüz
Şerife Yılmaz Gürbüz
EBErhan Başar
Erhan Başar
Stenotrophomonas maltophilia, yenidoğan ve ileri yaş grubundaki kişilerde, solunum yolu enfeksiyonları başta olmak üzere nozokomiyal ya da toplum kaynaklı çeşitli enfeksiyonlar ile ilişkilendirilmiş, kısıtlı tedavi seçeneği olan fırsatçı bir patojendir. Bakterinin antimikrobiyal direnci yıllar içinde artmakta ve coğrafi bölgeler arasında farklılıklar göstermektedir. Bu çalışma ile hastanemizde üç yıl boyunca izole edilen S. maltophilia suşlarının dağılımı ve antibiyotik duyarlılığının retrospektif olarak araştırılması amaçlanmıştır. Ocak 2022- Aralık 2024 tarihleri arasında çeşitli klinik örneklerden izole edilen S. maltophilia suşları incelenmiştir. Suşların identifikasyonu ve antimikrobiyal duyarlılığının belirlenmesi için Phoenix otomatize sistemi (Becton Dickinson Diagnostic Instrument Systems, Sparks, ABD) kullanılmıştır. Çalışma süresince toplam 233 S. maltophilia izolatı elde edilmiştir. Suşlar en sık solunum yolu örneklerinden (%66.5) izole edilmiştir. Suşların %60.3’ü çocuk ve yoğun bakımlarda tedavi gören hastalardan, %11.1’i ise poliklinikten başvuran hastalardan izole edilmiştir. Hastaların 157’si (%67.4) 65-95 yaş aralığında bulunmuştur. Suşların %90.12’si (210/233) trimetoprim/sülfametoksazole (TMP/SXT), %80.34’ü (184/229) ise levofloksasine duyarlı bulunmuştur. Sonuç olarak, verilerimiz yoğun bakımda yatan ileri yaş grubundaki kişilerin S. maltophilia enfeksiyonu gelişimi açısından dikkatle takip edilmesi gerektiğini düşündürmektedir. Hastanemizde izole edilen S. maltophilia suşları için en etkili antimikrobiyal TMP-SXT iken, yıllar içinde levofloksasin duyarlılığındaki azalma dikkat çekicidir. S. maltophilia enfeksiyonlarında önemli tedavi seçenekleri olan bu iki antimikrobiyal için duyarlılık durumu yeni çalışmalarla takip edilmelidir.